Novavax (NVAX) Short-term Investments (2010 - 2026)

Novavax's Short-term Investments history runs 15 years deep, the most recent figure standing at $562.0 million for Q1 2026.

• In Q1 2026, Short-term Investments rose 20.05% year-over-year to $562.0 million; the TTM figure through Mar 2026 stood at $562.0 million (up 20.05% YoY), while the FY2025 annual figure was $494.4 million, up 25.85% from the prior year.
• Short-term Investments was $562.0 million for Q1 2026 at Novavax, up from $494.4 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $562.0 million in Q1 2026 to a low of $335.9 million in Q3 2024.
• Historically, Short-term Investments has averaged $434.5 million across 3 years, with a median of $430.5 million in 2024.
• Biggest YoY gain for Short-term Investments was 47.34% in 2025; the steepest drop was 2.93% in 2025.
• A 3-year view of Short-term Investments shows it stood at $392.9 million in 2024, then gained by 25.85% to $494.4 million in 2025, then gained by 13.66% to $562.0 million in 2026.
• The last three Short-term Investments figures came in at $562.0 million (Q1 2026), $494.4 million (Q4 2025), and $494.9 million (Q3 2025), per Business Quant data.